BraTS Continuous Evaluation
Learn More Brain tumors are among the deadliest types of cancer. Specifically, glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma
Anti-PD1 Response Prediction Dream Challenge
LEARN MORE While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1 therapy,
CTD2 Chemosensitivity DREAM Challenge
Learn More The Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and
CTD^2 BeatAML DREAM Challenge
Learn More The goal of the Beat AML DREAM Challenge is to define patient subpopulations tailored to individual treatments by discovering (genomic
CTD^2 Pancancer Drug Activity DREAM Challenge
Learn More Over the course of two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive
Single-Cell Signaling in Breast Cancer DREAM Challenge
Learn More Signaling underlines nearly every cellular event. Individual cells, even if genetically identical, respond to perturbation in different ways. This underscores
ICGC-TCGA DREAM Somatic Mutation Calling – RNA Challenge
Learn More The ICGC-TCGA DREAM Somatic Mutation Calling - RNA Challenge (SMC-RNA) is an international effort to improve standard methods for identifying
SMC-DNA Meta
Learn More The ICGC-TCGA DREAM Somatic Mutation Calling Meta-pipeline Challenge (SMC-DNA Meta) (herein, The Challenge) is an international effort to improve standard
Broad-DREAM Gene Essentiality Prediction
Learn More Large-scale functional screening of cancer cell lines provides a complementary approach to cancer genome studies that aim to characterize the
DREAM 8 – HPN-DREAM Breast Cancer Network Inference Challenge
Learn More The overall goal of the Heritage-DREAM breast cancer network inference challenge is to quickly and effectively advance our ability to